#nepc — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #nepc, aggregated by home.social.
-
Cerity plumped its AUA by $1.2 trillion with its Verus Investments purchase, then a Chicago pension fund suddenly pulled incoming $13.8 billion in assets for a reason that should chill RIA rollups – RIABiz
Cerity plumped its AUA by $1.2 trillion with its Verus Investments purchase…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Personalfinance #Business #CerityPartners #HighTower #KurtMiscinski #Mariner #NEPC #PersonalFinance #VerusInvestments
https://www.newsbeep.com/us/588677/ -
Cerity plumped its AUA by $1.2 trillion with its Verus Investments purchase, then a Chicago pension fund suddenly pulled incoming $13.8 billion in assets for a reason that should chill RIA rollups – RIABiz
Cerity plumped its AUA by $1.2 trillion with its Verus Investments purchase…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Personalfinance #Business #CerityPartners #HighTower #KurtMiscinski #Mariner #NEPC #PersonalFinance #VerusInvestments
https://www.newsbeep.com/us/588677/ -
For this story, we asked whether we could explore expression (RNA & protein) in patient samples (PDXs, PDOs, cell lines, IHC of tumors) more sytematically and whether we could use #GPC3 as a #radiopharmaceutical target for #NEPC.
Turns out that GPC3 is highly enriched in patients with AR-/NE+ subtype of prostate cancers!
-
For this story, we asked whether we could explore expression (RNA & protein) in patient samples (PDXs, PDOs, cell lines, IHC of tumors) more sytematically and whether we could use #GPC3 as a #radiopharmaceutical target for #NEPC.
Turns out that GPC3 is highly enriched in patients with AR-/NE+ subtype of prostate cancers!
-
For this story, we asked whether we could explore expression (RNA & protein) in patient samples (PDXs, PDOs, cell lines, IHC of tumors) more sytematically and whether we could use #GPC3 as a #radiopharmaceutical target for #NEPC.
Turns out that GPC3 is highly enriched in patients with AR-/NE+ subtype of prostate cancers!